Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendrimer phthalocyanine micelle (DPc/m) is a nanotherapeutic photosensitizer formulation developed for photodynamic therapy (PDT). It consists of a third-generation dendritic phthalocyanine (DPc) core, typically containing zinc, encapsulated within a polymeric micelle composed of poly(ethylene glycol)-b-poly(L-lysine) or similar block copolymers. This micellar structure improves the aqueous solubility of the hydrophobic phthalocyanine and facilitates its accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. Upon excitation by light (typically at 671 nm), the DPc/m generates singlet oxygen and other reactive oxygen species (ROS), leading to localized oxidative stress and cell death. It has been studied primarily for the treatment of solid tumors and hollow organ cancers, such as bladder cancer, where it is often paired with specialized fiber-optic probes for uniform light delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dendrimer phthalocyanine micelle.